Investor & Media Home
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Learn more about our pipeline here.
Recent News
Apr 17, 2024
Mar 8, 2024
Mar 5, 2024
FRONT >> News > View All
View All Press Releases
Events & Presentations
Mar 11, 2024 at 10:00 AM EDT
Mar 5, 2024 at 2:10 PM EST
Feb 25, 2024 at 9:45 AM EST
FRONT > Events - View All
View All Events